Kajian In Silico Senyawa Turunan Kalkon sebagai Antikanker
DOI:
https://doi.org/10.25026/mpc.v9i1.309Abstract
Senyawa kalkon termasuk dalam famili flavonoid yang memiliki aktivitas seperti antimalarial, antioksidan, antimikroba, antikanker dan analgesik. Aktivitas antikanker senyawa kalkon berbasis 3,4-metilendioksi asetofenon di analisis melalui metode docking dengan adanya interaksi antara senyawa turunan kalkon dengan enzim topoisomerase II. Senyawa turunan kalkon berbasis 3,4-metilendioksi asetofenon dioptimasi dengan Hyperchem 8.0 dan di docking dengan MOE Chemical Computing Group. Interaksi antara senyawa turunan kalkon dengan enzim topoisomerase II berupa interaksi hidrogen dan arene hydrogen.
References
[1] WHO (diakses 06 November 2018). Cancer. http://www.who.int/cancer/en/
[2] Rahman, M. 2011. Chalcone : A Valueable Insight Into The Recent Advances And Potential Pharmacological Activities. Chemical Science Journal.
[3] Pingaew, R, et al. 2014. Synthesis, Biological Evaluation and Molecular Docking of Novel Chalcone-Coumarin Hybrids as Anticancer and Antimalarial Agents. European Journal of Medicinal Chemistry, 65-76.
[4] Prada-Gracia D. et al. 2016. Application of Computational Methods for Anticancer Drug Discovery, Design, and Optimization. Bol Med Hosp Infant Mex. http://dx.doi.org/10.1016/j.bmhimx.2016.10.006
[5] Jandial, Danielle D. Et al. 2014. Molecular Targeted Approaches To Cancer Therapy And Prevention Using Chalcones. Curr Cancer Drug Targets 14(2).
[6] Nath Dhar, Durga. 1981. The Chemistry of Chalcones and Related Compounds. SERBIULA (sistema Librum 2.0).
[7] Nitiss, J. L. 2009. Targetting DNA Topoisomerase II in Cancer Chemotherapy. Nature Reviews Cancer, 338-350.
[8] Cole JC, et al. 2005. Comparing protein-ligand docking programs is difficult. Proteins. Aug 15;60(3):325-32. Review. PubMed PMID: 15937897.
[9] Jadhav, Ahwini K, and Mohan Karupayyil. 2017. Molecular Docking Studies On Thirteen Fluoroquinolones With Human Topoisomerase II A And B. In Silico Pharmacology 5:4. Germany.
[10] Nasution, Mochammad, et al. 2016. Chalcone and Its Pyrazole Derivatives as Potential Plasmodium falciparum Lactate Dehydrogenase Inhibitor: In Silico Approach for New Antimalarial Drug. DOI:10.13140/RG.2.1.2887.3847.
[2] Rahman, M. 2011. Chalcone : A Valueable Insight Into The Recent Advances And Potential Pharmacological Activities. Chemical Science Journal.
[3] Pingaew, R, et al. 2014. Synthesis, Biological Evaluation and Molecular Docking of Novel Chalcone-Coumarin Hybrids as Anticancer and Antimalarial Agents. European Journal of Medicinal Chemistry, 65-76.
[4] Prada-Gracia D. et al. 2016. Application of Computational Methods for Anticancer Drug Discovery, Design, and Optimization. Bol Med Hosp Infant Mex. http://dx.doi.org/10.1016/j.bmhimx.2016.10.006
[5] Jandial, Danielle D. Et al. 2014. Molecular Targeted Approaches To Cancer Therapy And Prevention Using Chalcones. Curr Cancer Drug Targets 14(2).
[6] Nath Dhar, Durga. 1981. The Chemistry of Chalcones and Related Compounds. SERBIULA (sistema Librum 2.0).
[7] Nitiss, J. L. 2009. Targetting DNA Topoisomerase II in Cancer Chemotherapy. Nature Reviews Cancer, 338-350.
[8] Cole JC, et al. 2005. Comparing protein-ligand docking programs is difficult. Proteins. Aug 15;60(3):325-32. Review. PubMed PMID: 15937897.
[9] Jadhav, Ahwini K, and Mohan Karupayyil. 2017. Molecular Docking Studies On Thirteen Fluoroquinolones With Human Topoisomerase II A And B. In Silico Pharmacology 5:4. Germany.
[10] Nasution, Mochammad, et al. 2016. Chalcone and Its Pyrazole Derivatives as Potential Plasmodium falciparum Lactate Dehydrogenase Inhibitor: In Silico Approach for New Antimalarial Drug. DOI:10.13140/RG.2.1.2887.3847.
Downloads
Published
2019-04-30
How to Cite
Oktaviani, R., Arifian, H., Rahmadani, A., Zamruddin, N. M., & Rusli, R. (2019). Kajian In Silico Senyawa Turunan Kalkon sebagai Antikanker. Proceeding of Mulawarman Pharmaceuticals Conferences, 9(1), 22–26. https://doi.org/10.25026/mpc.v9i1.309
Issue
Section
Articles
